top of page
The Professional Network for Healthcare Experts
BioPorto advances US regulatory pathway for adult AKI test following FDA feedback
The company has expanded its US clinical validation study to support a future FDA submission for its adult NGAL kidney injury test while continuing to grow adoption of the biomarker in clinical practice.
nuaxia
Aug 212 min read
Lilly and Ascidian Enter $1.9bn Partnership to Advance RNA Exon Editing in Monogenic Kidney Disease
Eli Lilly and Ascidian Therapeutics have entered into a multi-year strategic collaboration worth up to $1.9bn, focused on developing RNA exon-editing therapies for undisclosed monogenic kidney diseases.
nuaxia
Jun 43 min read
bottom of page